<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Aquestive Therapeutics, Inc.

    Aquestive Therapeutics, Inc.

    Aquestive Therapeutics is a specialty pharmaceutical company that advances and com...

    Aquestive Therapeutics is a specialty pharmaceu...

    Filing Type:    PU
    Vaccinex, Inc.

    Vaccinex, Inc.

    Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...

    Vaccinex is a clinical-stage biotechnology comp...

    Filing Type:    PU
    H & G Science, Inc.

    H & G Science, Inc.

    H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...

    H&G Science aims to facilitate the safe and eff...

    Amount Raised:    $24,000.00
    Fundraising Status:    EC
    Filing Type:    CF
    Medivie USA Inc

    Medivie USA Inc

    Medivie Therapeutic is an Israeli public company, which developed Laboraide – a ...

    Medivie Therapeutic is an Israeli public compan...

    Filing Type:    RA
    Silk Road Medical, Inc.

    Silk Road Medical, Inc.

    Silk Road Medical is a medical device company focused on reducing the risk of stro...

    Silk Road Medical is a medical device company f...

    Filing Type:    PU
    Microbot Medical Inc.

    Microbot Medical Inc.

    Microbot™, which was founded in 2010 and commenced operations in 2011, became a ...

    Microbot™, which was founded in 2010 and comm...

    Filing Type:    PU
    Equillium, Inc.

    Equillium, Inc.

    Equillium is a biotechnology company leveraging deep understanding of immunobiolog...

    Equillium is a biotechnology company leveraging...

    Filing Type:    PU
    IMV Inc.

    IMV Inc.

    IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...

    IMV Inc. is a clinical stage biopharmaceutical ...

    Filing Type:    PU
    Iovance Biotherapeutics, Inc.

    Iovance Biotherapeutics, Inc.

    Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on th...

    Iovance Biotherapeutics (formerly traded as Lio...

    Filing Type:    PU
    ASLAN Pharmaceuticals Limited

    ASLAN Pharmaceuticals Limited

    ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company d...

    ASLAN Pharmaceuticals is a clinical-stage oncol...

    Filing Type:    PU
    Anchiano Therapeutics Ltd.

    Anchiano Therapeutics Ltd.

    We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on...

    We are Anchiano Therapeutics, a pivotal-stage b...

    Filing Type:    PU
    Forty Seven, Inc.

    Forty Seven, Inc.

    Forty Seven is a clinical-stage immuno-oncology company focused on developing nove...

    Forty Seven is a clinical-stage immuno-oncology...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.